

GLAXOSMITHKLINE PLC
Form 6-K
August 10, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 10 August 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

b) Position/status CEO

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each

ISIN: GB0009252882

b) Nature of the transaction Acquisition of ordinary shares under the Company's ShareReward Plan

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.79758 (partnership shares)
£16.79758 (matching shares)

d) Aggregated information
Aggregated volume Price

16 Ordinary shares

£16.7975

e) Date of the transaction

2016-08-09

f) Place of the transaction

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global Manufacturing & Supply

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of ordinary shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.79758 (partnership shares) £16.79758 (matching shares)
d) Aggregated information	16 Ordinary shares
Aggregated volume Price	£16.7975
e) Date of the transaction	2016-08-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	CFO
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of ordinary shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.79758 (partnership shares) £16.79758 (matching shares)
d) Aggregated information	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume Price	16 Ordinary shares £16.7975
e) Date of the transaction	2016-08-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ISIN: GB0009252882
b) Nature of the transaction	Acquisition of ordinary shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.7975 8 (partnership shares) £16.7975 8 (matching shares)
Aggregated information	
d) Aggregated volume Price	16 Ordinary shares £16.7975
e) Date of the transaction	2016-08-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr S A Hussain

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

b) Position/status President, Global
Pharmaceuticals

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

Ordinary shares of 25 pence
each

a) Description of the financial instrument
ISIN: GB0009252882

b) Nature of the transaction
Acquisition of ordinary shares
under the Company's
ShareReward Plan

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.79757 (partnership shares)
£16.79757 (matching shares)

d) Aggregated information
Aggregated volume Price
14 Ordinary shares
£16.7975

e) Date of the transaction 2016-08-09
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern
b) Position/status Chief Strategy Officer

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of ordinary shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.79758 (partnership shares) £16.79758 (matching shares)
d) Aggregated information Aggregated volume Price	16 Ordinary shares £16.7975
e) Date of the transaction	2016-08-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, HR
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of ordinary shares under the Company's ShareReward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.79758 (partnership shares) £16.79758 (matching shares)
d) Aggregated information Aggregated volume Price	16 Ordinary shares £16.7975

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2016-08-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
 b) Position/status SVP, Communications &
 Government Affairs
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each
 a) Description of the financial instrument
 ISIN: GB0009252882
 b) Nature of the transaction
 Acquisition of ordinary shares
 under the Company's
 ShareReward Plan
 c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.79758 (partnership shares)
 £16.79758 (matching shares)

d) Aggregated information
 Aggregated volume Price
 16 Ordinary shares
 £16.7975

e) Date of the transaction 2016-08-09
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance
 b) Position/status President, Pharmaceuticals
 R&D
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each
- a) Description of the financial instrument
- ISIN: GB0009252882
Acquisition of ordinary shares under the Company's ShareReward Plan
- b) Nature of the transaction
- Price(s) Volume(s)
c) Price(s) and volume(s) £16.79757 (partnership shares)
£16.79757 (matching shares)
- Aggregated information
- d) Aggregated volume Price 14 Ordinary shares
£16.7975
- e) Date of the transaction 2016-08-09
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms E Walmsley
b) Position/status CEO, GSK Consumer Healthcare
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each
- a) Description of the financial instrument
- ISIN: GB0009252882
- b) Nature of the transaction
- Acquisition of ordinary shares under the Company's

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

ShareReward Plan

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.7975 8 (partnership shares)
£16.7975 8 (matching shares)

Aggregated information
d) 16 Ordinary shares
Aggregated volume Price £16.7975

e) Date of the transaction 2016-08-09
f) Place of the transaction London Stock Exchange
(XLON)

a) Name Mrs V A Whyte
b) Position/status Company Secretary

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

Ordinary shares of 25 pence
each

a) Description of the financial instrument
ISIN: GB0009252882

b) Nature of the transaction
Acquisition of ordinary shares
under the Company's
ShareReward Plan

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.7975 8 (partnership shares)
£16.7975 8 (matching shares)

Aggregated information
d) 16 Ordinary shares
Aggregated volume Price £16.7975

e) Date of the transaction 2016-08-09
f) Place of the transaction London Stock Exchange
(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: August 10, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc